

# CITATION REPORT

List of articles citing

Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension

DOI: 10.7326/0003-4819-136-7-200204020-00008  
Annals of Internal Medicine, 2002, 136, 515-22.

**Source:** <https://exaly.com/paper-pdf/33877075/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
384	Prostacyclin for pulmonary hypertension. <b>2002</b> , CD002994		6
383	Treprostinil therapy for pulmonary artery hypertension. <b>2002</b> , 11, 1615-22		8
382	Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. <b>2002</b> , 360, 895-900		590
381	Pulmonary hypertension and the search for the selective pulmonary vasodilator. <b>2002</b> , 360, 886-7		23
380	Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. <i>International Journal of Cardiology</i> , <b>2002</b> , 86, 131-41	3.2	64
379	Chronic thromboembolic pulmonary hypertension. <b>2002</b> , 45, 203-12		14
378	Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: a review. <b>2003</b> , 36, 529-35		118
377	Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma. <b>2003</b> , 29, 293-313		67
376	[Sildenafil in the treatment of pulmonary hypertension]. <b>2003</b> , 59, 110-3		4
375	[Chronic thromboembolic pulmonary hypertension associated with endomyocardial fibrosis of the right ventricle]. <b>2003</b> , 39, 370-2		3
374	Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. <b>2003</b> , 78, 1207-13		91
373	[Sildenafil as a substitute for subcutaneous prostacyclin in pulmonary hypertension]. <b>2003</b> , 39, 476-7		1
372	Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. <b>2003</b> , 42, 158-64		290
371	Primary pulmonary hypertension. <b>2003</b> , 361, 1533-44		428
370	[Use of oral sildenafil (Viagra) in pulmonary hypertension after cardiac pediatric surgery]. <b>2003</b> , 22, 140-3		5
369	[Treatment of primary pulmonary hypertension with vasodilator drugs]. <b>2003</b> , 120, 194-6		
368	Cyclic nucleotide phosphodiesterase 5 and sildenafil: promises realized. <b>2003</b> , 63, 1209-11		17

367	Phosphodiesterase type 5 (PDE5) inhibitors. <b>2003</b> , 41, 249-306		23
366	Treatment of scleroderma: an update. <b>2003</b> , 12, 471-82		11
365	Treatment with sildenafil for the healing of refractory skin ulcerations in the antiphospholipid syndrome. <b>2003</b> , 12, 133-5		31
364	A novel mechanism for pulmonary arterial hypertension?. <b>2003</b> , 108, 1420-1		16
363	Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2003</b> , 167, 1139-41	10.2	211
362	Successful Withdrawal of Long-term Epoprostenol Therapy for Pulmonary Arterial Hypertension. <i>Chest</i> , <b>2003</b> , 124, 1612-1615	5.3	37
361	Evaluation and management of pulmonary hypertension in systemic sclerosis. <b>2003</b> , 15, 761-5		7
360	Recent advances in the treatment of pulmonary hypertension. <b>2003</b> , 16, 331-6		2
359	Advances in the treatment of secondary pulmonary hypertension. <b>2003</b> , 9, 139-43		24
358	Modulating the pulmonary circulation: an update. <b>2003</b> , 16, 59-64		2
357	Refractory pulmonary hypertension in a lupus patient with occult pulmonary vasculitis. <b>2003</b> , 9, 263-6		2
356	Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. <i>Chest</i> , <b>2003</b> , 123, 1293-5	5.3	101
355	Sildenafil no tratamento da hipertenso pulmonar associada a lpus eritematoso sistmico e sndrome antifosfolipica. <i>Jornal De Pneumologia</i> , <b>2003</b> , 29, 302-304		
354	Treatment of Pulmonary Arterial Hypertension with Sildenafil. <b>2004</b> , 39, 243-253		2
353	Acute respiratory distress syndrome (ARDS). <b>2004</b> , 15, 37-42		
352	Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2004</b> , 169, 39-45	10.2	207
351	Nitric oxide and other novel therapies for pulmonary hypertension. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2004</b> , 9, 1-8	2.6	16
350	Alternatives to nitric oxide. <b>2004</b> , 70, 119-31		22

349	Pilot assessment of the response of several pulmonary hemodynamic variables to sublingual sildenafil in candidates for heart transplantation. <b>2004</b> , 6, 615-7	35
348	Endothelin and pulmonary arterial hypertension. <b>2004</b> , 34, 442-53	29
347	Prostacyclin and its analogues in the treatment of pulmonary hypertension. <b>2004</b> , 102, 139-53	102
346	[Treatment of porto-pulmonary hypertension]. <b>2004</b> , 28 Spec No 2, B169-78	
345	[Treatment of porto pulmonary hypertension]. <b>2004</b> , 28 Spec No 2, B312-6	
344	Phosphodiesterase inhibitors in the management of primary pulmonary hypertension. <b>2004</b> , 19, 74-9	1
343	Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. <b>2004</b> , 94, 1475-7	107
342	Drug therapy of primary pulmonary hypertension. <b>2004</b> , 4, 75-85	13
341	[Therapeutic management of porto-pulmonary hypertension. Complication of portal hypertension: how to treat pleuro-pulmonary complications?]. <b>2004</b> , 21, 637-43	0
340	Iloprost en la hipertensi3 pulmonar tromboemb3lica cr3nica. <b>2004</b> , 40, 326-328	5
339	[Combined treatment with intravenous prostacyclin and sildenafil in patients with pulmonary hypertension: report of 4 cases]. <b>2004</b> , 122, 64-6	4
338	Iloprost for Chronic Thromboembolic Pulmonary Hypertension. <b>2004</b> , 40, 326-328	
337	Efficacy of Oral Sildenafil as Rescue Therapy in Patients With Severe Pulmonary Arterial Hypertension Chronically Treated With Prostacyclin. Long-Term Results. <b>2004</b> , 57, 946-951	2
336	Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. <b>2004</b> , 43, 68S-72S	108
335	Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. <b>2004</b> , 44, 1488-96	86
334	Sildenafil for pulmonary hypertension. <i>The Cochrane Library</i> , <b>2004</b> , CD003562	5.2 12
333	Eficacia del sildenafilo por v3a oral como terapia de rescate en pacientes con hipertensi3 arterial pulmonar severa en tratamiento cr3nico con prostaciclina. Resultados a largo plazo. <b>2004</b> , 57, 946-951	1
332	Treatment of pulmonary arterial hypertension. <b>2004</b> , 351, 1425-36	1338

331	Inhaled iloprost: in primary pulmonary hypertension. <b>2004</b> , 64, 763-73; discussion 774-5		17
330	Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and management. <b>2004</b> , 3, 339-52		39
329	Diagnosis and treatment of pulmonary arterial hypertension. <b>2004</b> , 22, 441-52, vii		5
328	Les patients atteints d'hypertension artérielle pulmonaire sévère s'aggravent sous iloprost et sont inefficaces de la jonction de sildenafil   Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension, H.A. Ghofrani, F. Rose, R.T. Schermuly, H. Olschewski, R. Wiedemann, A. Kreckel, N. Weissmann, S. Ghofrani, B. Enke, W. Seeger, F. Grimminger. <i>Am J Cardiol</i> , 13 (2003), pp. 158-164. <b>2004</b> , 23, 99-100		
327	[Treatments for pulmonary arterial hypertension]. <b>2004</b> , 25, 720-31		2
326	Use of sildenafil with inhaled nitric oxide in the management of severe pulmonary hypertension. <b>2004</b> , 18, 775-6		12
325	Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. <i>Chest</i> , <b>2004</b> , 125, 580-6	5-3	100
324	Current Management of Pulmonary Hypertension. <b>2004</b> , 11, 40-53		4
323	Acute effects of sildenafil in patients with primary pulmonary hypertension receiving epoprostenol. <b>2004</b> , 30, 135-45		18
322	Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. <i>Chest</i> , <b>2004</b> , 126, 35S-62S	5-3	382
321	Marked improvement with sildenafil in a patient with primary pulmonary hypertension unresponsive to epoprostenol. <b>2004</b> , 43, 945-50		8
320	Inhaled alternatives to nitric oxide. <b>2005</b> , 33, S188-95		27
319	Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. <i>Chest</i> , <b>2005</b> , 128, 2368-74	5-3	100
318	Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. <i>Chest</i> , <b>2005</b> , 128, 2363-7	5-3	130
317	Use of long-term combined therapy with inhaled iloprost and oral sildenafil in an adult patient with Eisenmenger syndrome. <b>2005</b> , 13, 312-4		18
316	Addition of oral sildenafil to beraprost is a safe and effective therapeutic option for patients with pulmonary hypertension. <b>2005</b> , 45, 286-9		33
315	The effect of sildenafil on pulmonary embolism-induced oxidative stress and pulmonary hypertension. <b>2005</b> , 101, 115-20, table of contents		71
314	Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. <b>2005</b> , 112, 2980-5		260

313	The acutely decompensated right ventricle: pathways for diagnosis and management. <i>Chest</i> , <b>2005</b> , 128, 1836-52	5-3	159
312	Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol. <b>2005</b> , 69, 461-5		45
311	[Medicinal vasoactive therapy of microcirculation disorders in rheumatoid arthritis]. <b>2005</b> , 64, 123-36		2
310	[Recommendations of the German Society of Rheumatology on therapy of pulmonary hypertension in patients with autoimmune diseases]. <b>2005</b> , 64, 93-5		
309	Combining treprostinil and sildenafil in the treatment of pulmonary hypertension. <b>2005</b> , 35, 684-5		4
308	Current treatment strategies for pulmonary arterial hypertension. <b>2005</b> , 258, 199-215		51
307	Methylthionium chloride: pharmacology and clinical applications with special emphasis on nitric oxide mediated vasodilatory shock during cardiopulmonary bypass. <b>2005</b> , 60, 575-87		30
306	When cure is care: Diagnosis and management of pulmonary arterial hypertension. <b>2005</b> , 17, 104-112		2
305	Lack of synergistic effect of molsidomine and sildenafil on development of pulmonary hypertension in chronic hypoxic rats. <b>2005</b> , 510, 87-96		16
304	Hemodynamic effects of sildenafil citrate and isosorbide mononitrate in men with coronary artery disease and erectile dysfunction. <b>2005</b> , 2, 407-14		15
303	Combination drug therapy in the management of pulmonary arterial hypertension. <b>2005</b> , 20, 177-82		4
302	Early haemodynamic benefit of sildenafil in patients with coexisting chronic thromboembolic pulmonary hypertension and left ventricular dysfunction. <b>2005</b> , 42, 41-5		33
301	[Pulmonary hypertension: pathophysiology, genetics and functional genomics]. <b>2005</b> , 46, 759-68		3
300	Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. <b>2005</b> , 100, 131-8		150
299	Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report. <b>2005</b> , 3, 26		26
298	One-year follow-up of the effects of sildenafil on pulmonary arterial hypertension and veno-occlusive disease. <b>2005</b> , 38, 185-95		36
297	Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. <b>2005</b> , 111, 3274-80		203
296	Treatment of pulmonary hypertension in the general adult intensive care unit: a role for oral sildenafil?. <b>2005</b> , 94, 774-7		24

295	Prostanoids and phosphodiesterase inhibitors in experimental pulmonary hypertension. <b>2005</b> , 67, 251-84	8
294	Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction. <b>2005</b> , 1, 283-93	34
293	Iloprost inhalation solution for the treatment of pulmonary arterial hypertension. <b>2005</b> , 6, 1921-30	15
292	Inhaled iloprost in pulmonary arterial hypertension. <b>2005</b> , 39, 1265-74	28
291	Prostacyclin does not inhibit rho-kinase: an implication for the treatment of pulmonary hypertension. <b>2005</b> , 45, 120-4	22
290	Advances in the medical treatment of pulmonary hypertension. <b>2005</b> , 28, 311-24	4
289	[Treatment of pulmonary arterial hypertension]. <b>2005</b> , 34, 1445-55	2
288	Sildenafil citrate therapy for pulmonary arterial hypertension. <b>2005</b> , 353, 2148-57	1843
287	Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction. <b>2005</b> , 32, 419-29, vi	34
286	Sildenafil for pulmonary hypertension. <b>2005</b> , 39, 869-84	34
285	Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. <i>International Journal of Cardiology</i> , <b>2005</b> , 99, 91-5	3.2 57
284	Novel use of sildenafil in the treatment of portopulmonary hypertension. <b>2005</b> , 24, 498-500	53
283	Severe left ventricular dysfunction secondary to primary pulmonary hypertension: bridging therapy with bosentan before lung transplantation. <b>2005</b> , 24, 777-80	7
282	Sildenafil selectively inhibits acute pulmonary embolism-induced pulmonary hypertension. <b>2005</b> , 18, 181-6	62
281	Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. <b>2005</b> , 99, 1501-10	70
280	Oral sildenafil reduces pulmonary hypertension after cardiac surgery. <b>2005</b> , 79, 194-7; discussion 194-7	108
279	Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors. <b>2005</b> , 6, 76	25
278	Drug treatment of pulmonary arterial hypertension: current and future agents. <b>2005</b> , 65, 1337-54	40

277	Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety. <b>2005</b> , 4, 531-40		18
276	Prostacyclin for pulmonary hypertension in adults. <i>The Cochrane Library</i> , <b>2005</b> , CD002994	5.2	22
275	Medical therapeutics for pulmonary arterial hypertension: from basic science and clinical trial design to evidence-based medicine. <b>2005</b> , 3, 347-60		2
274	Le sildñafil améliore les capacités d'exercice en condition hypoxique et hypobarique. <b>2005</b> , 22, 93-94		2
273	Ilprost for idiopathic pulmonary arterial hypertension. <b>2005</b> , 3, 215-23		7
272	Imatinib for the treatment of pulmonary arterial hypertension. <b>2005</b> , 353, 1412-3		377
271	Present and future treatment strategies for pulmonary arterial hypertension : focus on phosphodiesterase-5 inhibitors. <b>2006</b> , 5, 271-82		8
270	Treatment of pulmonary arterial hypertension with sildenafil: from pathophysiology to clinical evidence. <b>2006</b> , 20, 722-35		22
269	Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. <b>2006</b> , 114, 1482-9		489
268	Systemic and localized scleroderma. <b>2006</b> , 24, 374-92		98
267	Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers. <b>2006</b> , 44, 886-93		39
266	Efficacy of sildenafil as a rescue therapy for patients with severe pulmonary arterial hypertension and given long-term treatment with prostanoids: 2-year experience. <b>2006</b> , 25, 1353-7		31
265	Treatments for pulmonary arterial hypertension. <b>2006</b> , 100, 765-74		11
264	Hypertension artñielle pulmonaire. <b>2006</b> , 3, 1-27		2
263	Pulmonary arterial hypertension. <b>2006</b> , 12, 228-34		14
262	An evidence-based approach to the management of pulmonary arterial hypertension. <b>2006</b> , 21, 385-92		27
261	Experimental therapies for hypoxia-induced pulmonary hypertension during acute lung injury. <b>2006</b> , 25, 214-26		19
260	Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia. <b>2006</b> , 100, 2031-40		104



259	Pulmonary arterial hypertension: new insights and new hope. <b>2006</b> , 11, 6-17	46
258	Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan. <b>2006</b> , 36 Suppl 3, 16-24	49
257	First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. <b>2006</b> , 36 Suppl 3, 32-8	54
256	Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. <b>2006</b> , 5, 689-702	366
255	Intratracheal administration of sildenafil and surfactant alleviates the pulmonary hypertension in newborn piglets. <b>2006</b> , 69, 287-94	7
254	Hämodynamische Wirkungen der inhalativen Applikation von Milrinon und Iloprost bei der Evaluation von Herztransplantations-Kandidaten. <b>2006</b> , 20, 60-68	
253	A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. <b>2006</b> , 44, 372-6	76
252	[Beneficial effect of sildenafil following surgery for mitral stenosis complicated by pre-capillary pulmonary hypertension: report of two cases]. <b>2006</b> , 55, 286-90	1
251	Pharmacotherapy for idiopathic pulmonary arterial hypertension during the past 25 years. <b>2006</b> , 26, 68-94	12
250	Sildenafil for pulmonary arterial hypertension. <b>2006</b> , 2, 137-43	1
249	Sildenafil improves dynamic vascular function in the brain: studies in patients with pulmonary hypertension. <b>2006</b> , 21, 194-200	46
248	Treatment for Pulmonary Arterial Hypertension. <b>2006</b> , 99-118	1
247	Pulmonary Hypertension Secondary to Chronic Respiratory Disease. <b>2006</b> , 143-156	
246	Sildenafil for pulmonary arterial hypertension: when blue turns into white. <b>2006</b> , 7, 1801-10	4
245	Treatment with phosphodiesterase inhibitors type III and V: milrinone and sildenafil is an effective combination during thromboxane-induced acute pulmonary hypertension. <b>2006</b> , 96, 317-22	29
244	Demographic features, BMPR2 status and outcomes in distal chronic thromboembolic pulmonary hypertension. <b>2007</b> , 62, 617-22	26
243	Right ventricular diastolic dysfunction and the acute effects of sildenafil in pulmonary hypertension patients. <i>Chest</i> , <b>2007</b> , 132, 11-7	5:3 115
242	Effective inhaled drug administration to mechanically ventilated patients. <b>2007</b> , 4, 47-61	24

241	Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. <b>2007</b> , 115, 2331-9		118
240	Inhalation therapy in invasive and noninvasive mechanical ventilation. <b>2007</b> , 13, 27-38		44
239	Right ventricular dysfunction. <b>2007</b> , 13, 532-40		5
238	Management strategies for patients with pulmonary hypertension in the intensive care unit. <b>2007</b> , 35, 2037-50		204
237	Effect of sildenafil on hypoxia-induced changes in pulmonary circulation and right ventricular function. <b>2007</b> , 159, 196-201		28
236	A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. <b>2007</b> , 153, 1037-47		179
235	Effect of sildenafil on pulmonary artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devices. <b>2007</b> , 83, 68-71; discussion 71		73
234	Evidence-based pharmacologic management of pulmonary arterial hypertension. <b>2007</b> , 29, 2134-53		67
233	Management of pulmonary arterial hypertension with a focus on combination therapies. <b>2007</b> , 26, 437-46		59
232	Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension. <b>2007</b> , 26, 1079-83		19
231	Oral sildenafil therapy improves health-related quality of life and functional status in pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , <b>2007</b> , 119, 400-2	3.2	5
230	Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship. <i>International Journal of Cardiology</i> , <b>2007</b> , 120, 306-13	3.2	52
229	Standard therapies for pulmonary arterial hypertension. <b>2007</b> , 28, 91-115, viii		19
228	Prostanoid therapy for pulmonary arterial hypertension. <b>2007</b> , 28, 127-42; ix		24
227	The nitric oxide/cGMP signaling pathway in pulmonary hypertension. <b>2007</b> , 28, 143-67, ix		66
226	Combination therapy and new types of agents for pulmonary arterial hypertension. <b>2007</b> , 28, 169-85, ix		41
225	Exploiting the natriuretic peptide system for the treatment of pulmonary hypertension. <b>2007</b> , 7,		1
224	Therapeutic applications of sildenafil citrate in the management of paediatric pulmonary hypertension. <b>2007</b> , 67, 57-73		30

223	Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. <i>Chest</i> , <b>2007</b> , 131, 1917-28	53	421
222	Pulmonary Hypertension. <b>2007</b> ,		
221	Ilprost. <b>2007</b> , 1-10		
220	P. <b>2007</b> , 150-175		
219	Traitement médical de l'hypertension artérielle pulmonaire. <b>2007</b> , 56, S123-S136		
218	Does Sildenafil produce a sustained benefit in patients with pulmonary hypertension associated with parenchymal lung and cardiac disease?. <b>2007</b> , 47, 184-8		15
217	Treatment of refractory pulmonary arterial hypertension with inhaled epoprostenol in an infant with congenital heart disease. <b>2007</b> , 2, 194-8		5
216	Therapie der chronischen Thromboembolie (CTEPH). <b>2007</b> , 4, 30-38		0
215	Pulmonale Hypertonie. <b>2007</b> , 4, 283-302		2
214	Right ventricular function with hypoxic exercise: effects of sildenafil. <b>2007</b> , 102, 87-95		22
213	Pulmonary hypertension: current diagnosis and treatment. <b>2007</b> , 96, 527-41		53
212	Pulmonal arterielle Hypertonie. <b>2007</b> , 2, 101-119		1
211	Therapy of pulmonary arterial hypertension in systemic sclerosis: an update. <b>2007</b> , 9, 158-64		6
210	Quantitative analysis of sildenafil and desmethylsildenafil in human serum by liquid chromatography-mass spectrometry with minimal sample pretreatment. <b>2008</b> , 876, 283-7		18
209	Comparison of the effectiveness of oral sildenafil versus oxygen administration as a test for feasibility of operation for patients with secondary pulmonary arterial hypertension. <b>2008</b> , 29, 552-5		8
208	Bewegungstherapie bei pulmonaler Hypertonie. <b>2008</b> , 5, 98-102		
207	Interfield dysbalances in research input and output benchmarking: visualisation by density equalizing procedures. <b>2008</b> , 7, 48		17
206	Assessment of unmet needs and the lack of generalizability in the design of randomized controlled trials for scleroderma treatment. <b>2008</b> , 59, 706-13		10

205	Acute necrotising pulmonary vasculitis and pulmonary hypertension in a juvenile dog. <b>2008</b> , 49, 349-55		8
204	Emerging treatments for pulmonary arterial hypertension. <b>2008</b> , 2, 132-40		1
203	Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: a pilot study. <b>2008</b> , 13, 916-8		29
202	Oral phosphodiesterase type 5 inhibitors: nonerectogenic beneficial uses. <b>2008</b> , 5, 2502-18		37
201	Sildenafil: a review of its use in pulmonary arterial hypertension. <b>2008</b> , 68, 383-97		50
200	Cardiovascular consequences of pulmonary hypertension. <b>2008</b> , 43, 17-36; v		1
199	Long-term inhaled nitric oxide plus phosphodiesterase 5 inhibitors for severe pulmonary hypertension. <b>2008</b> , 27, 1326-32		18
198	Sustained benefit of tadalafil in patients with pulmonary arterial hypertension with prior response to sildenafil: a case series of 12 patients. <i>International Journal of Cardiology</i> , <b>2008</b> , 125, 416-7	3.2	23
197	Sildenafil improves endothelial function in patients with pulmonary hypertension. <b>2008</b> , 21, 172-7		18
196	Sildenafil for pulmonary hypertension: dose-dependent improvement in exercise performance. <b>2008</b> , 21, 516-21		7
195	Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. <b>2008</b> , 21, 824-32		57
194	A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. <b>2009</b> , 30, 394-403		440
193	Inhaled prostanoids in the therapy of pulmonary hypertension. <b>2008</b> , 21, 1-12		67
192	Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. <i>Chest</i> , <b>2008</b> , 134, 229-236	5.3	192
191	Treatment of severe pulmonary hypertension secondary to scleroderma: a three-drug approach. <b>2008</b> , 47, 511-3		9
190	Arterial pulmonary hypertension in noncardiac intensive care unit. <i>Vascular Health and Risk Management</i> , <b>2008</b> , 4, 1043-60	4.4	31
189	Clinical deterioration after sildenafil cessation in patients with pulmonary hypertension. <i>Vascular Health and Risk Management</i> , <b>2008</b> , 4, 1111-3	4.4	6
188	Anaesthesia and right ventricular failure. <b>2009</b> , 37, 370-85		46

187	Cardiac Physiology and Pharmacology. <b>2009</b> , 361-395	
186	Inhalative iloprost - pharmacology and clinical application. <b>2009</b> , 10, 2195-207	17
185	Conventional and targeted medical therapies. <b>2009</b> , 19 Suppl 1, 28-34	4
184	Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. <b>2009</b> , 154, 379-84, 384.e1-2	196
183	[Combination therapy for pulmonary arterial hypertension]. <b>2009</b> , 45, 36-40	1
182	No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. <b>2009</b> , 98, 4962-74	52
181	Sildenafil for the treatment of pulmonary hypertension in pediatric patients. <b>2009</b> , 30, 871-82	36
180	Mechanisms of drug combinations: interaction and network perspectives. <b>2009</b> , 8, 111-28	603
179	Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. <b>2009</b> , 22, 50-6	36
178	Successful up-front combination therapy in a patient with idiopathic pulmonary hypertension and patent foramen ovale: an alternative to epoprostenol therapy?. <b>2009</b> , 28, 651-3	9
177	Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. <b>2009</b> , 361, 1864-71	167
176	Combination Therapy for Pulmonary Arterial Hypertension. <b>2009</b> , 45, 36-40	
175	Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. <b>2009</b> , 49, 1343-52	48
174	Assessment of endpoints in pulmonary arterial hypertension associated with connective tissue disease. <b>2010</b> , 16 Suppl 1, S27-34	16
173	Oral sildenafil: potential role in heart transplantation. Review of the literature and personal experience. <b>2010</b> , 55, 291-5	11
172	Role of combination therapy in the treatment of pulmonary arterial hypertension. <b>2010</b> , 30, 390-404	7
171	Acute and long-term effects of inhaled iloprost in portopulmonary hypertension. <b>2010</b> , 16, 348-56	58
170	Sickle-cell anemia and pulmonary hypertension. <b>2010</b> , 22, 198-204	

169	The use of sildenafil to treat pulmonary hypertension associated with interstitial lung disease. <b>2010</b> , 15, 1226-32	29
168	Dramatic response of a patient with pregnancy induced idiopathic pulmonary arterial hypertension to sildenafil treatment. <b>2010</b> , 36, 414-7	7
167	Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy. <b>2010</b> , 2, 151-61	18
166	Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. <b>2010</b> , 121, 2045-66	367
165	Clinical use of sildenafil in pulmonary artery hypertension. <b>2010</b> , 4, 13-9	11
164	Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. <b>2010</b> , 55, 1915-22	381
163	Medical and surgical treatment of acute right ventricular failure. <b>2010</b> , 56, 1435-46	136
162	A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. <b>2010</b> , 104, 9-21	125
161	Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension. <b>2010</b> , 104 Suppl 1, S74-80	9
160	Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. <b>2010</b> , 159, 245-57	85
159	The effect of sildenafil citrate administration on selected physiological parameters of exercising Thoroughbred horses. <b>2010</b> , 42, 606-12	6
158	Current and future therapy for pulmonary hypertension in patients with right and left heart failure. <b>2010</b> , 8, 241-50	2
157	The extracellular signal-regulated kinase is involved in the effects of sildenafil on pulmonary vascular remodeling. <b>2010</b> , 28, 23-9	15
156	Hypertension artfielle pulmonaire. <b>2010</b> , 2, 27-37	
155	Hypertension pulmonaire (HTP). <b>2011</b> , 3, 25-33	
154	Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. <b>2011</b> , 30, 1327-33	69
153	Intravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertension. <b>2011</b> , 24, 169-73	7
152	Phosphodiesterase inhibitors: history of pharmacology. <i>Handbook of Experimental Pharmacology</i> , <b>2011</b> , 1-46	3.2 27

151	Role of phosphodiesterases in adult-onset pulmonary arterial hypertension. <i>Handbook of Experimental Pharmacology</i> , <b>2011</b> , 279-305	3.2	6
150	Inhaled iloprost for therapy in pulmonary arterial hypertension. <b>2011</b> , 5, 145-52		8
149	Tadalafil for the treatment of pulmonary arterial hypertension. <b>2011</b> , 5, 315-28		7
148	The management of acute pulmonary arterial hypertension. <b>2011</b> , 29, 153-75		19
147	Therapeutic strategies in pulmonary hypertension. <b>2011</b> , 2, 21		10
146	Vascular reactivity. 277-292		
145	New perspectives for the treatment of pulmonary hypertension. <i>British Journal of Pharmacology</i> , <b>2011</b> , 163, 125-40	8.6	47
144	Intraoperative device closure of atrial septal defects in the older population. <b>2011</b> , 6, 123		4
143	Combination therapy in pulmonary arterial hypertension: do we have the right strategy?. <b>2011</b> , 5, 191-205		5
142	Therapeutic combination of sildenafil and iloprost in a preterm neonate with pulmonary hypertension. <b>2011</b> , 46, 617-20		20
141	Combination therapy for the treatment of pulmonary arterial hypertension. <b>2011</b> , 5, 419-30		18
140	Pulmonary arterial hypertension: classification and therapy with a focus on prostaglandin analogs. <b>2012</b> , 19, 300-14		8
139	Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. <i>Chest</i> , <b>2012</b> , 142, 1383-1390	5.3	242
138	Inhalation therapy to treat pulmonary arterial hypertension. <b>2012</b> , 1, 577-88		4
137	Pulmonary hypertension-"state of the art" management in 2012. <b>2012</b> , 64, 60-73		2
136	[Effect of nebulised iloprost combined with inhaled nitric oxide and oral sildenafil on lung transplant patients. Therapeutic efficacy in pulmonary hypertension during surgery]. <b>2012</b> , 59, 142-9		4
135	Treatment of pulmonary arterial hypertension in connective tissue disease. <b>2012</b> , 72, 1039-56		2
134	Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study. <b>2012</b> , 12, 75		19

133	Managing an acutely ill patient with pulmonary arterial hypertension. <b>2013</b> , 7, 77-83		2
132	Current and future therapeutic targets for pulmonary arterial hypertension. <b>2013</b> , 14, 134-43		4
131	Portopulmonary hypertension. <b>2013</b> , 34, 719-37		5
130	Inhaled iloprost plus oral sildenafil in patients with severe pulmonary arterial hypertension delays the need for lung transplantation. <b>2013</b> , 45, 2347-50		9
129	Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry. <b>2013</b> , 32, 1114-22		74
128	Combination therapy in pulmonary arterial hypertension. <b>2013</b> , 111, 16C-20C		10
127	Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies. <b>2013</b> , 111, 1A-16A; quiz 17A-19A		48
126	Cyclic guanosine monophosphate signalling pathway in pulmonary arterial hypertension. <b>2013</b> , 58, 211-8		16
125	Combination therapy in pulmonary arterial hypertension. <b>2013</b> , 34, 841-55		11
124	Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. <i>Chest</i> , <b>2013</b> , 144, 952-958	5-3	224
123	Prenatal programming of pulmonary hypertension induced by chronic hypoxia or ductal ligation in sheep. <b>2013</b> , 3, 757-80		14
122	Combination pharmacotherapy in the treatment of pulmonary arterial hypertension: continuing education article. <b>2013</b> , 26, 18-28		2
121	Combination therapy in the management of pulmonary arterial hypertension. <b>2013</b> , 67, 13-23		16
120	Lack of a pharmacokinetic interaction between treprostinil diolamine and sildenafil in healthy adult volunteers. <b>2013</b> , 61, 444-51		8
119	Neonatal Pulmonary Hypertension. <b>2013</b> , 24, 1		6
118	The effect of pentoxifylline on penile cavernosal tissues in ischemic priapism-induced rat model. <b>2014</b> , 46, 1961-7		9
117	The cross talk between cGMP signal pathway and PKC in pulmonary endothelial cell angiogenesis. <b>2014</b> , 15, 10185-98		4
116	Pharmacologic management of perioperative pulmonary hypertension. <b>2014</b> , 63, 375-84		8



115	Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updates. <b>2014</b> , 9, S1-S15		7
114	Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension. <b>2014</b> , 9, S79-91		4
113	Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Intensive care management of pulmonary hypertension. <b>2014</b> , 9, S121-6		4
112	The role of endothelin-1 in pulmonary arterial hypertension. <b>2014</b> , 2014, 62-78		66
111	The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. <b>2014</b> , 2014, 257-90		10
110	Effects of sildenafil on prognosis in patients with pulmonary hypertension after left-sided valvular surgery. <i>Heart Lung and Circulation</i> , <b>2014</b> , 23, 680-5	1.8	11
109	Rechtsventrikuläre Funktion bei Implantation eines linksventrikulären Unterstützungssystems. <b>2014</b> , 28, 205-215		
108	Propylthiouracil Attenuates Experimental Pulmonary Hypertension via Suppression of Pen-2, a Key Component of Gamma-Secretase. <b>2015</b> , 10, e0137426		9
107	Pulmonary rehabilitation and exercise in pulmonary arterial hypertension: An underutilized intervention. <b>2015</b> , 11, 74-9		20
106	The role of calcium channel blockers for the treatment of pulmonary arterial hypertension: How much do we actually know and how could they be positioned today?. <b>2015</b> , 109, 557-64		24
105	Phosphodiesterase 5 inhibitors augment UT-15C-stimulated ATP release from erythrocytes of humans with pulmonary arterial hypertension. <b>2015</b> , 240, 121-7		8
104	Sildenafil versus nitric oxide for acute vasodilator testing in pulmonary arterial hypertension. <b>2015</b> , 5, 305-12		13
103	Development and validation of an ultra performance liquid chromatography tandem mass method for sildenafil and N-desmethyl sildenafil plasma determination and quantification. <b>2015</b> , 1001, 35-40		12
102	Adenosine-associated delivery systems. <b>2015</b> , 23, 580-96		22
101	Candidacy for lung transplant and lung allocation. <b>2015</b> , 25, 1-15		6
100	Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <b>2016</b> , 102 Suppl 2, ii67-85		43
99	[Treatment of acute and chronic right ventricular failure]. <b>2016</b> , 111, 463-80		1
98	Survival with sildenafil and inhaled iloprost in a cohort with pulmonary hypertension: an observational study. <b>2016</b> , 16, 5		8

97	Determination and quantitation of sildenafil and its major metabolite in the breast milk of a lactating woman. <b>2016</b> , 120, 100-5	9
96	Combination Therapy for Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis. <b>2016</b> , 32, 1520-1530	39
95	Pulmonary Hypertension in Infants, Children, and Young Adults. <b>2017</b> , 69, 2551-2569	78
94	Liposomal-delivery of phosphodiesterase 5 inhibitors augments UT-15C-stimulated ATP release from human erythrocytes. <b>2017</b> , 12, 114-119	1
93	A review of therapeutic agents for the management of pulmonary arterial hypertension. <b>2017</b> , 11, 46-63	8
92	Pediatric Perioperative Pulmonary Arterial Hypertension: A Case-Based Primer. <b>2017</b> , 4,	2
91	Anesthesia and Intensive Care Management for Cardiac Transplantation. <b>2018</b> ,	
90	Critical Care. <b>2018</b> , 209-215	
89	Inhalation of repurposed drugs to treat pulmonary hypertension. <b>2018</b> , 133, 34-44	11
88	Cardiac Physiology and Pharmacology. <b>2019</b> , 424-457.e17	1
87	A meta-analysis of randomized controlled trials in targeted treatments of chronic thromboembolic pulmonary hypertension. <b>2019</b> , 13, 467-479	2
86	Advances in targeted therapy for chronic thromboembolic pulmonary hypertension. <b>2019</b> , 24, 949-965	12
85	Iloprost delivered via the BREELIB nebulizer: a review of the clinical evidence for efficacy and safety. <b>2019</b> , 13, 1753466619835497	5
84	Nepilysin inhibition for pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled, proof-of-concept trial. <i>British Journal of Pharmacology</i> , <b>2019</b> , 176, 1251-1267	8.6 15
83	Phosphodiesterase 5 inhibitors for pulmonary hypertension. <i>The Cochrane Library</i> , <b>2019</b> , 1, CD012621	5.2 32
82	Real-life experience of inhaled iloprost for patients with pulmonary arterial hypertension: Insights from the Spanish REHAP registry. <i>International Journal of Cardiology</i> , <b>2019</b> , 275, 158-164	3.2 7
81	Inhaled Iloprost and Oral Sildenafil Combination Therapy: Is it a Chance for Heart Transplant Candidacy?. <i>Heart Lung and Circulation</i> , <b>2020</b> , 29, 1039-1045	1.8
80	Simultaneous determination and determination of sildenafil and its active metabolite in human plasma using LC-MS/MS method. <i>Biomedical Chromatography</i> , <b>2020</b> , 34, e4927	1.7 1

79	Does combination therapy work in chronic thromboembolic pulmonary hypertension?. <i>IJC Heart and Vasculature</i> , <b>2020</b> , 29, 100544	2.4	1
78	Outcomes of Pulmonary Arterial Hypertension Are Improved in a Specialty Care Center. <i>Chest</i> , <b>2020</b> , 158, 330-340	5.3	7
77	Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and Prostacyclin Pathways. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2021</b> , 26, 453-462	2.6	4
76	Repurposing of the PDE5 Inhibitor Sildenafil for the Treatment of Persistent Pulmonary Hypertension in Neonates. <i>Current Medicinal Chemistry</i> , <b>2021</b> , 28, 2418-2437	4.3	2
75	The Value of Heart Rhythm Complexity in Identifying High-Risk Pulmonary Hypertension Patients. <i>Entropy</i> , <b>2021</b> , 23,	2.8	
74	Life-threatening PPHN refractory to nitric oxide: proposal for a rational therapeutic algorithm. <i>European Journal of Pediatrics</i> , <b>2021</b> , 180, 2379-2387	4.1	7
73	Method development and validation of sildenafil, N-desmethylsildenafil and N1,N4-desmethylsildenafil by LC-MS/MS and its application. <i>Analytical Biochemistry</i> , <b>2021</b> , 631, 114355	3.1	1
72	Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities. <i>Pharmacology &amp; Therapeutics</i> , <b>2021</b> , 226, 107858	13.9	2
71	Acute Right Ventricular Failure. <i>Respiratory Medicine</i> , <b>2015</b> , 161-205	0.2	2
70	Potential Cardiac Applications of Phosphodiesterase Type-5 Inhibition. <b>2004</b> , 207-237		1
69	Transitions and Combination Therapy for Pulmonary Arterial Hypertension. <b>2008</b> , 337-362		1
68	Modulating cGMP to treat lung diseases. <i>Handbook of Experimental Pharmacology</i> , <b>2009</b> , 469-83	3.2	8
67	Prostacyclins. <i>Handbook of Experimental Pharmacology</i> , <b>2013</b> , 218, 177-98	3.2	4
66	THE SYSTEMIC SCLERODERMAS AND RELATED DISORDERS. <b>2005</b> , 442-471		1
65	Long-term results after addition of sildenafil in idiopathic PAH patients on bosentan. <i>Southern Medical Journal</i> , <b>2006</b> , 99, 880-3	0.6	14
64	Reversal of experimental pulmonary hypertension by PDGF inhibition. <i>Journal of Clinical Investigation</i> , <b>2005</b> , 115, 2811-21	15.9	764
63	Identification of cytosolic phosphodiesterases in the erythrocyte: a possible role for PDE5. <i>Medical Science Monitor</i> , <b>2011</b> , 17, CR241-7	3.2	12
62	Collective review: perioperative uses of inhaled nitric oxide in adults. <i>Heart Surgery Forum</i> , <b>2004</b> , 7, E584-97		16

61	Sildenafil in the treatment of pulmonary hypertension. <i>Vascular Health and Risk Management</i> , <b>2006</b> , 2, 411-22	4.4	88
60	Lung Transplantation: Timing, Perioperative Considerations and Postoperative Outcome. <i>Advances in Pulmonary Hypertension</i> , <b>2004</b> , 3, 9-18	0.5	2
59	Oral Therapies for PAH: State-of-the-Art and Investigational Approaches. <i>Advances in Pulmonary Hypertension</i> , <b>2006</b> , 5, 13-17	0.5	3
58	Surgical Treatment of Pulmonary Arterial Hypertension. <i>Advances in Pulmonary Hypertension</i> , <b>2010</b> , 9, 31-39	0.5	1
57	Hetero-Tricyclic Lead Scaffold as Novel PDE5A Inhibitor for Antihypertensive Activity: In Silico Docking Studies. <i>Current Computer-Aided Drug Design</i> , <b>2019</b> , 15, 318-333	1.4	1
56	Inhaled Medications Employed in Critically Ill Patients. <b>2021</b> , 169-188		
55	Clinical efficacy, safety, tolerability, and survival outcome of long-term inhaled iloprost treatment in the management of pulmonary arterial hypertension: Data from prospective multicenter observational OPTION study. <i>Anatolian Journal of Cardiology</i> , <b>2021</b> , 25, 721-732	0.8	0
54	Scleroderma-Associated Pulmonary Hypertension: Who's at Risk and Why. <i>Advances in Pulmonary Hypertension</i> , <b>2002</b> , 1, 5-9	0.5	
53	Inhaled Iloprost for Treatment of Pulmonary Arterial Hypertension. <i>Advances in Pulmonary Hypertension</i> , <b>2002</b> , 1, 16-21	0.5	2
52	Angeborene Herzfehler im Erwachsenenalter. <b>2003</b> , 166-175		
51	Deep Vein Thrombosis, Pulmonary Embolism, and Primary Pulmonary Hypertension. <b>2003</b> , 205-227		
50	Resoluço do "shunt" direita-esquerda aps uso do sildenafil como tratamento de hipertenso pulmonar primria. <i>Jornal De Pneumologia</i> , <b>2003</b> , 29, 305-308		
49	NO pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. <b>2004</b> , 163-168		
48	Pulmonale Hypertonie [Cor pulmonale. <b>2004</b> , 1201-1216		1
47	Sildenafil in pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2004</b> , 169, 1256; author reply 1256-7	10.2	
46	Sovremennyye predstavleniya o roli prostaglandinov v lechenii bol'nykh legochnoy gipertenziei. <i>Systemic Hypertension</i> , <b>2004</b> , 1, 7-10	1.6	
45	Tratamento da hipertenso arterial pulmonar. <i>Jornal Brasileiro De Pneumologia</i> , <b>2005</b> , 31, S17-S23	1.1	0
44	Management of the Acutely Ill Patient with Pulmonary Arterial Hypertension. <b>2006</b> , 254-265		

43	Anesthesia for Pediatric Organ Transplantation. <b>2006</b> , 895-974		
42	Pulmonary Arterial Hypertension. <b>2006</b> , 543-548		
41	Medical Therapy For Pulmonary Arterial Hypertension. <i>Tuberculosis and Respiratory Diseases</i> , <b>2006</b> , 60, 142	3.2	1
40	The etiology and pathogenesis of pulmonary arterial hypertension. <i>Cor Et Vasa</i> , <b>2006</b> , 48, 108-113	0.3	2
39	Advances in Prostanoid Therapy: New Studies, New Methods of Delivery. <i>Advances in Pulmonary Hypertension</i> , <b>2006</b> , 5, 23-30	0.5	1
38	Reinventing the Wheel. <b>2006</b> ,		
37	Intensive management of acute right heart failure. <i>Korean Journal of Pediatrics</i> , <b>2007</b> , 50, 1041	2.4	1
36	Pharmacological Support of the Failing Right Ventricle. <i>Yearbook of Intensive Care and Emergency Medicine</i> , <b>2008</b> , 88-100		0
35	Combination Therapies in Pulmonary Arterial Hypertension. <i>Advances in Pulmonary Hypertension</i> , <b>2008</b> , 7, 235-242	0.5	0
34	Lungengefäßkrankungen. <b>2008</b> , 433-528		
33	Inhaled Prostanoids in the Therapy of Pulmonary Hypertension. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , <b>2008</b> , 080116123756336-12		
32	Drugs Acting on the Respiratory System. <i>Competency-based Critical Care</i> , <b>2009</b> , 135-142		
31	Chronic Pulmonary Hypertension. <b>2009</b> , 483-505		
30	PULMONARY ARTERIAL HYPERTENSION. <b>2009</b> , 401-415		
29	Cor Pulmonale. <b>2010</b> , 1326-1355		
28	Endothelial dysfunction in pulmonary hypertension. <b>2010</b> , 81-102		1
27	Combination Therapy for Pulmonary Arterial Hypertension. <b>2011</b> , 1509-1520		
26	Phosphodiesterase Inhibitors in the Treatment of Pulmonary Hypertension. <b>2011</b> , 1477-1485		

- 25 Prostacyclin and Prostaglandins. **2011**, 1451-1463
- 24 Critical Care. **2011**, 121-125
- 23 Komplikationsmanagement. **2013**, 283-332
- 22 Right Heart Failure. **2014**, 311-329
- 21 Diagnosis and Treatment of Pulmonary Arterial Hypertension. **2014**, 1-33
- 20 [Clinical utility of inhaled iloprost in pulmonary arterial hypertension]. *Archivos De Cardiologia De Mexico*, **2014**, 84, 202-10 0.2 1
- 19 Combination Therapy for the Treatment of Pulmonary Arterial Hypertension. *Respiratory Medicine*, **2015**, 377-396 0.2
- 18 Diagnosis and Treatment of Pulmonary Arterial Hypertension. **2015**, 4105-4133
- 17 Komplikationsmanagement. **2017**, 225-262
- 16 Postoperatives VAD-Management. **2017**, 161-223
- 15 A Comparison of Two Different Doses of Sildenafil in Pulmonary Arterial Hypertension – A Prospective Randomised Controlled Study. *Journal of Cancer Prevention & Current Research*, **2017**, 7, 1.3
- 14 Case Report: Inhaled Nitroglycerine as an Alternative to Inhaled Nitric Oxide in the Acute Treatment of Pulmonary Hypertension and Impending Acute Right Ventricular Failure in the Intensive Care Unit.
- 13 [Advantages and limitations of initial combination therapy in pulmonary arterial hypertension patients in Russia]. *Terapevticheskii Arkhiv*, **2020**, 92, 80-85 0.9 5
- 12 Angeborene Herzfehler im Erwachsenenalter. **2005**, 174-183
- 11 Chronisches Cor pulmonale. **2005**, 277-294
- 10 Pharmacological Support of the Failing Right Ventricle. **2008**, 88-100
- 9 PDE5 Inhibitors and the cGMP Pathway in Pulmonary Arterial Hypertension. **2008**, 305-319
- 8 Hua Fo tablets tainted with sildenafil-like compound. *Cmaj*, **2002**, 166, 1568 3.5 0

7	Pulmonary Hypertension in Intensive Care Units: An Updated Review. <i>Tanaffos</i> , <b>2019</b> , 18, 180-207	0.5	3
6	Impact of pregnancy in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: case series and literature review.. <i>Lupus Science and Medicine</i> , <b>2022</b> , 9,	4.6	0
5	Efficacy and safety of sequential combination therapy for pulmonary arterial hypertension: A meta-analysis of Randomized-Controlled Trials. <b>2022</b> , 76, 102144		
4	PDE5 inhibitors and male reproduction: Is there a place for PDE5 inhibitors in infertility clinics or andrology laboratories?.		1
3	Model-Informed drug development of gastroretentive release systems for sildenafil citrate. <b>2023</b> , 182, 81-91		0
2	Combination therapy of newly diagnosed intermediate-risk pulmonary arterial hypertension: A review. <b>2022</b> , 24, 688-695		0
1	Surgical and Device Interventions in the Treatment of Chronic Thromboembolic Disease.		0